Chronic myeloid leukemia BCR/ABL1 mutation clonal evolution and treatment strategies
10.3760/cma.j.issn.1009-9158.2012.01.002
- VernacularTitle:慢性髓细胞白血病BCR/ABL1突变克隆演化和治疗策略
- Author:
Ping ZHU
- Publication Type:Journal Article
- Keywords:
Leukemia,myelogenous,chronic;
Fusion proteins,bcr-abl;
Piperazines;
Pyrimidines;
Protein-tyrosine kinases;
Mutation
- From:
Chinese Journal of Laboratory Medicine
2012;35(1):2-5
- CountryChina
- Language:Chinese
-
Abstract:
Application of imatinib has made a lot of chronic myeloid leukemia (CML) patients longterm survival,but the CML BCR/ABL1 kinase domain mutations (KDM) will result in drug resistance of imatinib.There are many KDM types.The different types appear randomly.The leukemic clone with different KDM characteristics has a certain evolution.In the period of imatinib treatment,a higher degree of drug resistance mutations in cells likely to develop as the dominant clone.It is suggested that the treatment of imatinib-resistant CML in addition to efforts to develop next-generation tyrosine kinase inhibitors outside,but also consider the use of traditional medicine to help cure.
